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prospective 6-month pilot study of smokers not
intending to quit
Riccardo Polosa1,2,4*, Pasquale Caponnetto1,2, Marilena Maglia1,2, Jaymin B Morjaria3 and Cristina Russo1,2Abstract
Background: Electronic cigarettes (e-Cigs) are an attractive long-term alternative nicotine source to conventional
cigarettes. Although they may assist smokers to remain abstinent during their quit attempt, studies using first
generation e-Cigs report low success rates. Second generation devices (personal vaporisers - PVs) may result in much
higher quit rates, but their efficacy and safety in smoking cessation and/or reduction in clinical trials is unreported.
Method: We conducted a prospective proof-of-concept study monitoring modifications in smoking behaviour of 50
smokers (unwilling to quit) switched onto PVs. Participants attended five study visits: baseline, week-4, week-8, week-12 and
week-24. Number of cigarettes/day (cigs/day) and exhaled carbon monoxide (eCO) levels were noted at each visit. Smoking
reduction/abstinence rates, product usage, adverse events and subjective opinions of these products were also reviewed.
Results: Sustained 50% and 80% reduction in cigs/day at week-24 was reported in 15/50 (30%) and 7/50 (14%)
participants with a reduction from 25cigs/day to 6cigs/day (p < 0.001) and 3cigs/day (p < 0.001), respectively. Smoking
abstinence (self-reported abstinence from cigarette smoking verified by an eCO ≤10 ppm) at week-24 was observed in
18/50 (36%) participants, with 15/18 (83.3%) still using their PVs at the end of the study. Combined 50% reduction and
smoking abstinence was shown in 33/50 (66%) participants. Throat/mouth irritation (35.6%), dry throat/mouth (28.9%),
headache (26.7%) and dry cough (22.2%) were frequently reported early in the study, but waned substantially by
week-24. Participants’ perception and acceptance of the products was very good.
Conclusion: The use of second generation PVs substantially decreased cigarette consumption without causing
significant adverse effects in smokers not intending to quit.
Trial registration: (ClinicalTrials.gov Identifier: NCT02124200)
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Tobacco harm reductionBackground
Most smokers want to quit and make attempts to do so,
but the majority of these attempts fail largely because the
powerful addictive qualities of nicotine and non-nicotine
sensory and behavioural cues [1,2]. For those willing to quit,
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unless otherwise stated.intervention for smoking cessation can support their quit
attempts and can double or triple quit rates [3,4]. However,
outside the context of a rigorous clinical trial (where there
tends to be intensive support), their efficacy rates are some-
what lower, not exceeding 10% [5,6]. Several population-
based studies evaluating the value of pharmacotherapy
outside the context of clinical trials have also shown modest
quit rates with antismoking medications [7-9]. Conse-
quently, the need for novel and more efficient approaches
to smoking cessation interventions is unquestionable.
Electronic cigarettes (e-Cigs) are an attractive long-term
alternative source of nicotine to conventional cigarettes
because of their many similarities with smoking [10,11].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Polosa et al. BMC Public Health 2014, 14:1159 Page 2 of 9
http://www.biomedcentral.com/1471-2458/14/1159Moreover, users report buying them to reduce cigarette
consumption, to relieve tobacco withdrawal symptoms, to
quit, and to continue having a ‘smoking’ experience, but
with reduced health risks [12,13]. Two RCTs have recently
reported disappointingly low quit rates with e-Cigs; 4–
8.7% for the ECLAT study in Italy [14] and 4–7.3% for the
ASCEND study in New Zealand [15]. A likely explanation
for the poor results is to be attributed to the unsatisfactory
quality of the products under investigation, essentially
first-generation cig-alike devices consisting of small re-
chargeable batteries and disposable cartridges (Figure 1A).
Their lithium battery allowed only a limited number of
puffs and required frequent recharging. Reliability was
questionable due to the high frequency of technical
malfunctions. Moreover, both products were not very
efficient at delivering nicotine [16]. Presumably, these prod-
ucts were not performing adequately as cigarette substitutes.
Second-generation devices (or personal vaporizers (PVs))
are equipped with higher-capacity lithium batteries, much
efficient vaporizing systems and cartridges that can be
refilled with liquid solutions mainly consisting of propyl-
ene glycol (PG), glycerol, distilled water, flavourings andSecond Ge




Figure 1 E-cigarettes are battery-powered electronic nicotine delivery
of providing inhaled doses of nicotine by way of a vaporized solution
physical sensation similar to that of inhaled tobacco smoke, while no smok
of the current study, E-cigarettes can be distinct in first generation (A) and
mimic the size and look of conventional cigarettes and consist of small lith
with a liquid that bathes the atomizer); their batteries may be disposable (t
consist mainly of higher-capacity (larger) rechargeable lithium batteries and
vials). In the most recent atomizers you can simply change the atomizer he
thus reducing the operating costs. They do not resemble conventional cignicotine (i.e. e-Liquid) (Figure 1B). These devices assent to
a more fulfilling vaping experience with the choice of an
extensive number of puffs and e-liquid aromas, and thicker
vapor [12,13]. Moreover, nicotine delivery to the blood-
stream using second-generation devices is consistently
superior compared to “cig-alikes” [17,18].
Consequently, PV use may result in higher quit rates
compared to “cig-alikes”. With this in mind, we designed
a prospective proof-of-concept study to monitor possible
modifications in daily cigarette consumption in smokers
switching to second generation PVs focusing on smoking
reduction and abstinence. We also monitored product
use and adverse events and evaluated participants’ per-
ception and acceptance of the product.
Methods
Participants
Healthy smokers 18–60 years old, smoking ≥15 conven-
tional cigarettes per day (cig/day) for at least 10 years were
recruited using anti-smoking leaflets and by an ap-
proved kiosk located in the atrium of the university hos-
pital (AOU ‘Policlinico-V.Emanuele’) promoting smokingFirst Generation ECs(‘cigalikes’)
neration ECs (personal vaporizers)
A
B
device (ENDD) resembling a cigarette designed for the purpose
to the respiratory system. These devices provide a flavor and
e or combustion is actually involved in its operation. For the purpose
second generation devices (B). First-generation devices, generally
ium batteries and cartomizers (i.e. cartridges, which are usually prefilled
o be used once only) or rechargeable. Second-generation devices,
atomizers with the ability to refill them with liquid (sold in separate
ad (resistance and wick) while keeping the body of the atomizer,
arettes.
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Cura del Tabagismo, Università di Catania, Italy).
Intent to quit smoking or wishing to do so in the next
30 days was investigated at screening using 2 questions:
“Do you intend to quit in the next 30 days?” and “Are you
interested in taking part in one of our smoking cessation
programs?”. If subjects answered “no” to both questions,
then they were considered eligible for inclusion. If they
answered “yes”, they were invited to attend our standard
smoking cessation program; of all the subjects approached,
9 (7 M, 2 F) requested to attend professional smoking
cessation services and were excluded from the study
(Figure 2).
None of the participants reported a history of alcohol
and illicit drug use, major depression or other psychi-
atric conditions. The study protocol was approved by
the University of Catania Ethics Review Board and sub-
jects gave written consent prior to participation.
Study design and baseline measures
Eligible participants were invited to use a second gener-
ation device (EGO/CE4 model, filled with tobacco aroma
e-Liquid containing 9 mg/ml nicotine) and were followed-
up prospectively for 6 months. They attended a total ofFigure 2 Recruitment and flow of subjects within the study. A total of
cig/day for at least 10 years) responded to the advert; of these, 9 subjects w
assistance with quitting (these were then invited to attend the local smoki
counselling and pharmacotherapy for nicotine dependence). The remainin
not considered eligible because of the exclusion criteria. In the end, 50 vol
generation PV kit with a full supply of tobacco aroma e-liquid containing 9
lost to follow-up due to failure of attending their control visits. Overall 38 pfive study visits at our smoking cessation clinic (CPCT,
Università di Catania, Italy) comprising of a baseline visit
and four follow-up visits at week-4, 8, 12, and 24
(Figure 2).
At baseline, basic demographic and smoking history
were taken together with scoring of their level of nicotine
dependence by means of Fagerstrom Test of Nicotine
Dependence (FTND) questionnaire [19]. Subjective ratings
of depression were assessed with the Beck Depression
Inventory (BDI) [20]. Additionally, levels of carbon mon-
oxide in exhaled breath (eCO) were measured using a
portable device (Micro CO, Micro Medical Ltd, UK).
Participants were then given a second generation PV
and a full supply of tobacco aroma e-Liquid containing 9
mg/ml nicotine for 4 weeks (14 vials in total). Commer-
cially available PV kits (EGO/CE4 model with a recharge-
able 3.7 V - 650mAh lithium-ion battery, charger, and CE4
atomizer) and e-Liquids (Tuscan Reserve; FlavourArt –
Italy, www.flavourart.it, and Calliope; DEA Flavour – Italy,
www.flavourart.it; both consisting of a similar PG/VG
base) were purchased from local vapeshops out of a gener-
ous grant by LIAF (Lega Italiana Anti Fumo). These prod-
ucts are among the most popular in Italy and were
selected because of positive reviews in specialized forums.72 subjects with specifically predefined smoking criteria (smoking ≥15
ere not included in the study because they spontaneously seek
ng cessation clinic, which offers standard support with cessation
g 63 subjects consented to participate into the study; of these, 13 were
unteers were included in the study and were issued with a second
mg/ml nicotine. By the end of the study, a total of 12 subjects were
articipants were available for analyses at week-24 follow-up visit.
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and use the e-Cig. Key troubleshooting was addressed and
phone numbers were supplied for both technical and
medical assistance.
Participants were permitted to use the study products
ad libitum (up to a maximum of 5 ml/day; i.e. half vial)
in the anticipation of reducing the number of cig/day
smoked, and to fill a 4-weeks’ study diary recording
product use, number of conventional cigarettes smoked,
and adverse events. The participants were invited to
attend at week-4, week-8, and week-12 to have their eCO
levels measured, and to return their study diaries and
unused study products. At these visits participants
received further free e-Liquid refills together with the
study diaries for the residual study periods.
Participants returned for a final visit at week-24 during
which product use (total e-Liquid volume per day and fre-
quency of use), number of cig/day (from which smoking
reduction and abstinence could be computed), eCO level
and a subjective rating of the usefulness of the study prod-
ucts were assessed. For the latter, participants were asked
to rate their level of satisfaction with the products com-
pared to conventional cigarettes using a visual analogue
scale (VAS) from 0 to 10 points (0 = being ‘completely
unsatisfied’, 10 = ’fully satisfied’); on the same scale, they
also rated helpfulness (in keeping them from smoking)
and whether they would recommend the PV to a friend
who wanted to stop/reduce smoking. Adverse events were
obtained from their study diaries.
No emphasis on encouragement, motivation and re-
ward for the smoking cessation-related efforts were
provided during the study. Although participants were
encouraged to use these products, they were told that
they were at liberty to smoke their own brand conven-
tional cigarettes as they wished.
Study outcome measures
Sustained 50% reduction in the number of cig/day at week-
24 from baseline (reducers) [21] was defined as sustained
self-reported 50% reduction in the number of cig/day
compared to baseline for the 30 days period prior to week-
24 study visit (eCO levels were measured to verify smoking
status and confirm a reduction compared to baseline).
Sustained 80% reduction in the number of cig/day
(heavy reducers) and sustained smoking abstinence at
week-24 from baseline (quitters) were defined as sus-
tained self-reported 80% reduction in the number of
cig/day compared to baseline and complete self-reported
abstinence from tobacco smoking (not even a puff ) for
the 30 days period prior to week-24 study visit respect-
ively. eCO levels were measured to verify smoking status
and confirm a reduction compared to baseline for the
former and an eCO concentration of ≤10 ppm for the
quitters, respectively.Smokers who failed to meet the above criteria at the
final week-24 follow-up visit were categorized as reduc-
tion/cessation failures (failures).
Adverse events were obtained from study diaries;
withdrawal symptoms were reviewed at each visit by
asking about the presence/absence of irritability, restless-
ness, difficulty concentrating, increased appetite/weight
gain, depression or insomnia.
Statistical analyses
As this was a proof-of-concept pilot study no previous
data for PVs could be used for power calculation. How-
ever, by considering the results from our previous smok-
ing reduction and cessation study with first generation
e-cigs (i.e. cig-alikes) [22], we estimated that a sample of
50 subjects would have been adequate.
Primary and secondary outcome measures were com-
puted by including all enrolled participants - assuming
that all those individuals who were lost to follow-up are
classified as failures (intention-to-treat analysis). Paramet-
ric and non-parametric data were expressed as mean
(±SD) and median (interquartile range (IQR)) respectively.
Paired and unpaired non-parametric, and parametric data
were analysed using Wilcoxon Signed rank test and Mann
Whitney U test, and student’s t test respectively. Correla-
tions were calculated using Spearman’s Rho correlation.




After considering study inclusion and exclusion criteria,
a total of 50 (M 30; F 20; mean (±SD) age of 41 (±8.9)
years) regular smokers (mean (±SD) pack/yrs of 31.3
(±13.9)) consented to participate and were included in
the study (Table 1; Figure 2). Retention rate in this study
was high, with thirty-eight (76%) participants completing
all study visits and attending their final follow-up visit at
week-24. Baseline characteristics of those who were lost
to follow-up were not significantly different from partici-
pants who completed the study.
Changes in smoking behaviour
Participants’ smoking status at baseline and at 24-week is
shown on Table 2. Taking the whole cohort of participants
(n = 50), an overall 80% reduction in median cig/day use
from 25 to 5 was observed by the end of the study
(p < 0.001). Sustained 50% reduction in the number of cig/
day at week-24 was shown in 15/50 (30%) participants,
with a median of 25 cig/day (IQR 20, 30) decreasing
significantly to 6 cig/day (IQR 3.5, 6) (p < 0.001). Of these
tobacco smoke reducers, seven (14%) could be classified as
sustained heavy reducers (at least 80% reduction in the
number of cig/day) at week-24. They had a median
Table 1 Baseline subjects demographics
Parameter Mean (±SD)
Subjects eligible for inclusion
(n = 50)
Age 41.0 (±8.9)
Sex 30 M; 20 F
Smoking Pack Years 31.3 (±13.9)




Cigarettes/day 25 (20, 30)*
eCO 23 (17, 32.8)*
†Subjects available for week-24
analyses (n = 38)
Age 40.7 (±8.6)
Sex 24 M; 14 F
Smoking Pack Years 31.1 (±15)




Cigarettes/day 25 (20, 28.8)*
eCO 22.5 (16.3, 32)*
Abbreviations: SD Standard Deviation, M Male, F Female, FTND Fagerstrom Test of
Nicotine Dependence, eCO exhaled carbon monoxide, IQR interquartile range.
*Non-parametric data expressed as median (IQR).
†Subjects excluding those lost-to-follow-up.
Table 2 Subjects characteristics at baseline and after
24 weeks of personal vaporiser use





>80% reducers ) reduction
in cigarette smoking (n = 15)
Age 39.9 (±8.7)†
Sex 10 M; 5 F
Smoking Pack Years 31.1 (±16.5)†
Cigarettes/day 25 (20, 30)* 6 (3.5, 6)* <0.001
eCO 18 (13, 32.5)* 10 (7, 11.5)* <0.001
Sustained >80% (excluding
quitters) reduction in
cigarette smoking (n = 7)
Age 40.3 (±11.2)†
Sex 6 M; 1 F
Smoking Pack Years 32.6 (±20.6)†
Cigarettes/day 25 (18, 32.5)* 3 (3, 5)* <0.001
eCO 17 (13, 33)* 10 (5, 10)* 0.016
Sustained 100% (quitters)
reduction in cigarette
smoking (n = 18)
Age 40.2 (±8.9)†
Sex 12 M; 6 F
Smoking Pack Years 30.9 (±13.5)†
igarettes/day 25 (20.5, 25)* 0 (0, 0)* <0.001
eCO 23 (17.5, 29.3)* 3 (2.3, 4)* <0.001
Smoking Failure (<50%
smoking reduction) (n = 5)
Age 45.0 (±7.3)†
Sex 2 M; 3 F
Smoking Pack Years 32 (±18.5)†
Cigarettes/day 20 (20, 25)* 20 (20, 20)* 0.732
eCO 18 (16, 32)* 28 (17, 31)* 0.819
Lost to Follow-up (n = 12)
Age 42.2 (±10.2)
Sex 6 M; 6 F
Smoking Pack Years 31.9 (±10.6)
Cigarettes/day 25 (20, 30) N/A N/A
eCO 24 (19.8, 34.5) N/A N/A
Abbreviations: SD Standard Deviation, M Male, F Female, eCO exhaled
carbon monoxide.
‡p value – within group Wilcoxon Signed Rank Test.
†Parametric data expressed as mean (±SD).
*Non-parametric data expressed as median (interquartile range (IQR)).
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decreasing significantly to 3 cig/day (IQR 3, 5) (p < 0.001).
There were 18/50 (36%) quitters in total, with 15/18
(83.3%) still using their PVs by the end of the study. Over-
all, combined sustained 50% reduction and smoking
abstinence was shown in 33/50 (66%) participants, with a
median of 25 cig/day (IQR 20, 30) decreasing significantly
to 3 cig/day (IQR 0, 5) (p < 0.001), which is equivalent to
an overall 88% reduction. Details of mean conventional
cigarette use and eCO levels throughout the study are
shown in Figures 3 and 4, respectively.
Product use
Details of median amount of e-Liquid (millitres/day
(mLs/day)) used are shown on Figure 5. The reported
use of e-Liquid used was very variable within and among
failures, reducers, and quitters. For the whole group that
completed the all the visits (n = 38) the median (IQR)
usage over the 24 weeks was 2.85mLs/day (2.2, 3.9). Of
note, the overall amount of e-Liquid consumed was
marginally higher when these summary statistics were
computed with the exclusion of the five participants
who failed (failures) to give up smoking conventional
cigarettes, i.e. reducers and quitters combined; the
amount increasing to a median (IQR) of 3.2mLs/day(2.5, 3.9). Comparisons between overall e-Liquid use and
main study outcomes (i.e. failures, reducers and quitters)
are summarised on Table 3. In particular, no correlations
were observed between daily consumption of e-Liquid
Figure 3 Changes in the mean (±SD) number of conventional
cigarettes use per day for each study subgroups throughout
the study.
Figure 5 Changes in the mean (±SD) daily e-Liquid consumption
per day (mLs/day) for each study subgroups throughout the study.
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nificantly less e-Liquid than reducers/quitters. Further-
more, correlations between e-Liquid use at week-4 and
baseline FTND, pack/yrs and cig/day were weak and in-
significant. Likewise, no significant relationships were
observed between baseline FTND, pack/yrs and cig/day
and e-Liquid use at all subsequent study visits.Adverse events
Frequently reported adverse events in regular PV users
were throat/mouth irritation (35.6%), dry throat/mouth
(28.9%), headache (26.7%) and dry cough (22.2%) (Table 4).
These events were most commonly reported at the begin-
ning of the study and appeared to wane spontaneously by
the end of the study. Of note, typical withdrawal symp-
toms of smoking cessation were not reported (i.e. depres-
sion, anxiety, insomnia, irritability, hunger, constipation).
Moreover, there were no reported serious adverse events
(i.e. events requiring unscheduled visit to the family practi-
tioner or hospitalisation) during the study.Figure 4 Changes in the mean (±SD) exhaled carbon monoxide
(ppm) for each study subgroups throughout the study.Product preferences
The PV users rated scores well above the mean for satis-
faction and for helpfulness (enabling them to refrain
from smoking), their mean (±SD) VAS values being 6.7
(±2.6) and 7.4 (±2.9) respectively. Moreover, participants
recommended the use of PVs to friends or relatives who
wanted to stop/reduce smoking, the mean (±SD) VAS
value being 8.1 (±2.3). Predictably, PVs rated even higher
scores when these summary statistics were computed
with the exclusion of the study failures. Conversely,
products perception and acceptance by those who failed
to remain abstinent or reduce smoking was poor; the
mean (±SD) VAS values for satisfaction and for helpful-
ness being 2.0 (±1.2) and 0.8 (±1.1), respectively. As ex-
pected, these individuals were unlikely to recommend
PV use to friends or relatives; the mean (±SD) VAS value
being 3.6 (±2.6).
The overall participants’ perception and acceptance of
the product was good also because of its ease of use and
general lack of technical malfunctions. Only three study
participants could not use the product as recommended
and were retrained. One participant reported a faulty
atomizer, and two had faulty chargers; replacements
were given to them.Discussion
Efficacy and safety of second generation PVs in long-
term smoking cessation and/or smoking reduction
studies have never been investigated. Here, we show for
the first time that use of a second generation PV
substantially decreases cigarette consumption without
causing significant side effects in smokers not intending
to quit. Participants were enthusiastic about using these
products, the majority (i.e. 76%) completing the study
with an overall quit rate of 36%. A further 30% of the
participants were able to sustain ≥50% cigarette by the
end of the study.
Table 3 Comparisons between average daily e-Liquid consumption (mLs/day) and study outcome measures




1.98 (1.4, 3.2) 3.03 (2.2, 3.9) 2.85 (2.2, 3.9) 2.85 (2.2, 3.2) 3.2 (2.5, 3.9)
‡p value VS Failures - <0.001 0.010 0.013 0.002
Abbreviations: mL millilitres, n number of subjects, IQR interquartile range.
‡p value – between group Mann Whitney U Test.
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view of the fact that all smokers in the study were, by
inclusion criteria, not interested in quitting. Moreover,
though not directly comparable with standard smoking
cessation and/or reduction studies because of its design,
success rates in the present study are not only higher
than those obtained with pharmaceutical products for
the treatment of nicotine addiction [23,24], but also
greater than those of first generation “cig-alikes” [14,22].
In particular, comparison of current results with those
obtained in a similar prospective 6-month pilot study
with first generation “cig-alikes” published a few years
ago [22] shows improvement in quit rates with PVs
(22.5% for “cig-alike” users vs 36% for PVs users).
An explanation for the large success rate may be attrib-
uted to the high level of satisfaction with the performance
of second generation PVs as cigarette substitutes. The
high-capacity lithium battery did not require frequent
recharge, and the efficient vaporizing systems allowed an
uninterrupted vaping experience with sufficient number of
puffs through the whole day. Moreover, the reliability of
the PVs under investigations was more than satisfactory
with only a few reported technical malfunctions. Although
not specifically measured in this study, nicotine absorption
using second-generation devices has been shown to be
consistently superior compared to “cig-alikes” [17,18]. TheTable 4 Common adverse events reported by participants wh
Adverse Event
(AE) 4-week 8-week
no. pts reporting AEs/total
no. pts (%)




16/45 (35.6%) 9/43 (20.9%)
Dry throat/mouth 13/45 (28.9%) 10/43 (23.3%)
Headache 12/45 (26.7%) 9/43 (20.9%)
Dry cough 10/45 (22.2%) 7/43 (16.3%)
Dizziness§ 7/45 (15.6%) 7/43 (16.3%)
Nausea 6/45 (13.3%) 5/43 (11.6%)
Sore throat 4/45 (8.9%) 3/43 (7.0%)
Palpitations 3/45 (6.7%) 3/43 (7.0%)
Choking sensation 2/45 (4.4%) 1/43 (2.3%)
*Throat and mouth irritation were described either as tickling, itching, or burning se
§Dizziness, was also used to mean vertigo and light-headedness.high level of satisfaction with the product under investiga-
tion is substantiated by the notion that 30 out of the 38
who attended the last study visit were still using their PVs.
This together with the high retention rate and elevated
rating in likeability scores indicates that quality and
attractiveness of the study product may be playing a vital
role in attaining large success rates. Nonetheless, no
correlations were observed between daily consumption of
e-Liquid and success rates suggesting that multiple mech-
anisms are at play.
Throat/mouth irritation, and dry throat/mouth, head-
ache and dry cough were frequently reported at the begin-
ning of the study. These are likely to be secondary to
exposure to PG mist generated by the PVs; exposure to PG
mist may occur from smoke generators in discotheques,
theatres, and aviation emergency training and is known to
cause ocular, mouth, throat, upper airway irritation and
cough [25,26]. However, with the exception of headache
(a highly unspecific symptom), the irritative symptoms –
and particularly dry cough - appeared to wane spontan-
eously with time. Of note, typical withdrawal symptoms of
smoking cessation were not reported during the course of
the study. It is possible that the PVs under investigation by
providing a coping mechanism for conditioned smoking
cues could mitigate withdrawal symptoms associated with
smoking reduction and smoking abstinence. Dizziness,o completed all study visits
Study Visits
12-week 24-week
s/total no. pts reporting AEs/total
no. pts (%)
no. pts reporting AEs/total
no. pts (%)
7/41 (17.1%) 4/38 (10.5%)
9/41 (22.0%) 7/38 (18.4%)
8/41 (19.5%) 8/38 (21.1%)
5/41 (12.2%) 2/38 (5.3%)
5/41 (12.2%) 3/38 (7.9%)
5/41 (12.2%) 5/38 (13.2%)
1/41 (2.4%) 1/38 (2.6%)
0/41 (0%) 0/38 (0%)
0/41 (0%) 0/38 (0%)
nsation.
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but these were not common and substantially declined
with time. The substantial reduction in the frequency of
dizziness and the lack of reported palpitation at later time
points may be due to the improved familiarisation with
the puffing technique and/or to individual adjustments/
reductions in e-liquid consumption. In contrast from other
ENDDs such some heat-and-burn platforms that can
generate toxic levels of eCO [27], the products under
investigation lead to substantial reduction in eCO levels, as
expected in this vapour category [14,22,28]. Although larger
and longer studies will be required for a full assessment of
their adverse events, the present findings add to the current
evidence that vaping is by far a less harmful alternative to
tobacco smoking [29,30].
There are some limitations in our study. Firstly, this
was a small uncontrolled study, hence the results should
be interpreted with caution. However, it would have
been quite problematic to have a placebo arm in a study
in which smokers were not interested in quitting. Sec-
ondly, 32.5% of the participants failed to attend their
final follow-up visit, but this is not unexpected in a
smoking cessation study and study outcome measures
were computed by intention-to-treat analysis. Thirdly,
because of its unusual design (smokers not willing to
quit, PVs were used throughout the entire study period)
this is not an ordinary cessation study and therefore
direct comparison with other smoking cessation prod-
ucts cannot be made. Fourthly, assessment of withdrawal
symptoms in our study was not rigorous and it is likely
that was liable to recall bias. Therefore, the reported lack
of withdrawal symptoms in the study participants should
be considered with caution. Lastly, because only a single
nicotine strength (i.e. 9 mg/mL) and a single aroma (i.e.
tobacco flavour) were investigated in this study, it is
possible that we failed to further maximize success rates.
It is now known that unrestricted access to a wider
selection in e-Liquid nicotine strength and flavour
variability play a pivotal role in the attractiveness and
success rates of these products [31,32].Conclusions
Complete tobacco cessation is the best outcome for
smokers, but the powerful addictive qualities of nicotine
and of the ritualistic behavior of smoking create a huge
hurdle, even for those with a strong desire to quit. To-
bacco harm reduction (THR), the substitution of low-risk
nicotine products for cigarette smoking, is a realistic strat-
egy for smokers who have difficulty quitting. E-cigarettes
are the newest and most promising products for THR
[33]. This approach has been recently exploited to reduce
or reverse the burden of harm in smokers with mental
health disorders and chronic airway disease [34,35].E-cigarette is an attractive long-term alternative and safer
source of nicotine to conventional cigarette [11,12]. Since
their invention in 2003, there has been constant innovation
and development of more efficient and appealing products.
Here we show for the first time that second generation
PVs can substantially decrease cigarette consumption with-
out causing significant side effects in smokers not intend-
ing to quit. Moreover, overall participants’ perception and
acceptance of these products was very good, in particular
for those who quit or reduced smoking. Compared to our
earlier work with first generation “cig-alikes” [14,22], tech-
nical problems and difficulties in use familiarization with
second generation PVs were negligible. Improved products
reliability and attractiveness might have contributed to the
very low number of study failures and lost to follow-up
and high success rates thus confirming the notion that
these products are attractive substitutes for conventional
cigarettes. Although large and carefully conducted RCTs
will be required to confirm these preliminary encouraging
observations, the notion that second generation PVs can
substantially decrease cigarette consumption in smokers
not intending to quit should be taken into consideration by
regulatory authorities seeking to adopt proportional
measures for the vapour category [36].
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